Qin Yang

Dr. Qin Yang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
LCLijun Cai
Lijun Cai
STShuang Tang
Shuang Tang
YLYin Liu
Yin Liu
YZYingwan Zhang
Yingwan Zhang
QYQin Yang
Qin Yang
Background: This study aims to utilize Weighted Gene Co-expression Network Analysis (WGCNA) and Support Vector Machine (SVM) algorithm for screening biomarkers and constructing a diagnostic model for Parkinson’s disease.Methods: Firstly, we conducted WGCNA analysis on gene expression data from Parkinson’s disease patients and control group using three GEO datasets (GSE8397, GSE20163, and GSE20164) to identify gene modules associated with Parkinson’s disease. Then, key genes with significantly differential expression from these gene modules were selected as candidate biomarkers and validated using the GSE7621 dataset. Further functional analysis revealed the important roles of these genes in processes such as immune regulation, inflammatory response, and cell apoptosis. Based on these findings, we constructed a diagnostic model by using the expression data of FLT1, ATP6V0E1, ATP6V0E2, and H2BC12 as inputs and training and validating the model using SVM algorithm.Results: The prediction model demonstrated an AUC greater than 0.8 in the training, test, and validation sets, thereby validating its performance through SMOTE analysis. These findings provide strong support for early diagnosis of Parkinson’s disease and offer new opportunities for personalized treatment and disease management.Conclusion: In conclusion, the combination of WGCNA and SVM holds potential in biomarker screening and diagnostic model construction for Parkinson’s disease.

10 January 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
LCLijun Cai
Lijun Cai
YLYin Liu
Yin Liu
STShuang Tang
Shuang Tang
SDSong Deng
Song Deng
LZLi Zhang
Li Zhang
QYQin Yang
Qin Yang
Investigate irisin’s therapeutic potential in Parkinson’s disease (PD). Clinical data from 120 PD patients and 120 controls were analyzed. MPTP-induced PD mice and LPS-stimulated BV2 microglia models were used. In vivo, mice were divided into control, PD, and PD + Irisin groups for behavioral and histological assessments. In vitro, LPS-stimulated BV2 cells were treated with irisin or PBS. RNA sequencing, immunohistochemistry, and Western blot evaluated autophagy, inflammation, and ubiquitination pathways. PD patients exhibited increased TNF-α and IL-1β but decreased irisin levels. In PD mouse models, irisin improved motor deficits, increased nigrostriatal neuron numbers, restored tyrosine hydroxylase expression, and reduced α-synuclein aggregation. It also suppressed microglial inflammation and promoted anti-inflammatory polarization. Mechanistically, irisin enhanced autophagic flux, regulated RAGE ubiquitination mediated by PAFAH1B1, and inhibited neuroinflammation via the TFEB-NLRP3 axis. Specifically, PAFAH1B1 regulated RAGE expression through K61 and K169 sites on K48-linked polyubiquitin chains. Additionally, irisin restored lysosomal function by promoting TFEB nuclear translocation, enhancing NLRP3 inflammasome degradation, and reducing inflammatory factor secretion, thus alleviating neuroinflammation. Irisin alleviates PD pathology by modulating autophagy and ubiquitination pathways, suggesting its potential as a novel immunomodulatory target for PD.